FN2 Earnings Intelligence
SYK expanded earnings history
Stryker Corporation (SYK) quarterly earnings scorecards, market reactions, transcript intelligence, and historical context.
Earnings History
Stryker Corporation
The quarter supports a constructive operating-growth case through strong procedural demand, capital backlog and Mako momentum, but the narrowed guidance and supply disruption show that execution and margin risks remain material.
Stryker Corporation
A late-quarter cyber incident disrupted Stryker's manufacturing and revenue recognition, producing a Q1 2026 EPS miss of 12.8% ($2.60 vs $2.98 estimated) and a revenue miss of 5.0% ($6.02B vs $6.34B estimated). Organic sales growth slowed to 2.4%, well below the full-year target. Management maintained full-year guidance of 8%–9.5% organic growth and $14.90–$15.10 adjusted EPS, implying confidence that deferred revenue will recover in subsequent quarters. Strategic initiatives — the Amplitude Vascular acquisition, a new Ortho Tech segment, and record Mako installations — signal continued investment in growth despite the setback. The stock fell 6.5% on the print but has partially recovered, recently trading at $346.59 versus a $381.79 consensus target.
Stryker Corporation
The call supports a constructive operating thesis: strong procedure volumes, Mako adoption, product launches, international expansion, and tuck-in M&A underpin raised 2026 guidance. That support is conditional, with tariffs, regulation, reimbursement, competition, and macro demand as material offsets.
Stryker Corporation
The current analysis supports a constructive operating picture: Stryker paired 9.5% organic growth with margin expansion, record Mako installations, and raised full-year guidance. The counterweight is execution risk from tariffs, supply-chain pressure, competition, and Inari integration; the unavailable prior-quarter analysis limits trend comparison.
Stryker Corporation
The current analysis supports a constructive operating trajectory: strong organic growth, demand for capital products, product launches, and international expansion were accompanied by a raised full-year organic-growth outlook. The case is tempered by tariff exposure, integration execution, pricing and margin questions, and the absence of reported-versus-consensus actuals in the supplied scorecard.
Stryker Corporation
The supplied analysis supports a constructive but conditional view: Stryker's innovation, procedural-volume exposure, focused M&A, and portfolio repositioning provide a path to continued growth, while integration, dilution, competitive, and margin risks require monitoring.
Get the SYK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.